| P50 | author | Sina Bavari | Q32637684 |
| P2093 | author name string | Bing Li | |
| | Norton P Peet | |
| | Terry L Bowlin | |
| | Michelle M Butler | |
| | Ramdas Pai | |
| | Steven C Cardinale | |
| | Jonathan E Nuss | |
| P2860 | cites work | Botulinal neurotoxins: revival of an old killer | Q23832313 |
| | Botulinum Toxin as a Biological Weapon: Medical and Public Health Management | Q23832736 |
| | Modification-specific proteomics: strategies for characterization of post-translational modifications using enrichment techniques | Q24628360 |
| | Identification of small molecule inhibitors of anthrax lethal factor | Q27642936 |
| | Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine | Q27666091 |
| | Crystal structure of botulinum neurotoxin type A and implications for toxicity | Q27765727 |
| | Profiling the specific reactivity of the proteome with non-directed activity-based probes | Q28200208 |
| | Botulinum and tetanus neurotoxins: structure, function and therapeutic utility | Q28609172 |
| | Proteolysis of SNAP-25 by types E and A botulinal neurotoxins | Q28609208 |
| | Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design | Q28750297 |
| | Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency | Q30423794 |
| | Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A | Q33294825 |
| | Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase | Q33637465 |
| | Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin | Q73120963 |
| | Identification of proteins containing cysteine residues that are sensitive to oxidation by hydrogen peroxide at neutral pH | Q74037270 |
| | Intimate details of the most poisonous poison | Q74133716 |
| | Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1' binding subsite | Q77357157 |
| | Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease | Q84458383 |
| | Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease | Q33722985 |
| | Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors | Q33739700 |
| | Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons | Q34154552 |
| | Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. | Q34157031 |
| | Analysis of botulinum neurotoxin serotype A metalloprotease inhibitors: analogs of a chemotype for therapeutic development in the context of a three-zone pharmacophore | Q34317228 |
| | Pharmacophore Refinement Guides the Rational Design of Nanomolar-Range Inhibitors of the Botulinum Neurotoxin Serotype A Metalloprotease | Q34353299 |
| | Clostridium botulinum: a bug with beauty and weapon | Q34412430 |
| | Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases | Q34444412 |
| | Biological and chemical agents: a brief synopsis | Q34488054 |
| | Microbiological, biological, and chemical weapons of warfare and terrorism | Q34695957 |
| | Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes | Q35060579 |
| | Therapy and prophylaxis of inhaled biological toxins | Q35148875 |
| | Identification of the major steps in botulinum toxin action | Q35639122 |
| | An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. | Q35669634 |
| | Botulin toxin: a weapon in terrorism | Q35686984 |
| | Botulinum toxins in neurological disease | Q35759634 |
| | Medical aspects of biologic toxins | Q35869555 |
| | The medicinal chemistry of botulinum, ricin and anthrax toxins | Q36079816 |
| | The evolving field of biodefence: therapeutic developments and diagnostics | Q36085668 |
| | Bacteria as potential tools in bioterrorism, with an emphasis on bacterial toxins | Q36091510 |
| | A new wrinkle on pain relief: re-engineering clostridial neurotoxins for analgesics | Q36101373 |
| | Expanding use of botulinum toxin. | Q36180106 |
| | Medical aspects of toxin weapons. | Q36222475 |
| | Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry | Q37323247 |
| | Targeted covalent drugs of the kinase family | Q37770660 |
| | Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. | Q39742947 |
| | Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors. | Q39885183 |
| | Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. | Q40461076 |
| | Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A. | Q41940551 |
| | Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons | Q42602928 |
| | Irreversible inhibition of the bacterial cysteine protease-transpeptidase sortase (SrtA) by substrate-derived affinity labels. | Q43002164 |
| | A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity | Q44249536 |
| | Proteolysis of synthetic peptides by type A botulinum neurotoxin | Q44592997 |
| | Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease | Q44792229 |
| | Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. | Q45951244 |
| | Substrate recognition strategy for botulinum neurotoxin serotype A. | Q46801352 |
| | Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. | Q52099909 |
| | Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation | Q58120767 |
| | Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A | Q62730269 |
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 7338-7348 | |
| P577 | publication date | 2011-10-26 | |
| P1433 | published in | Bioorganic & Medicinal Chemistry | Q2904200 |
| P1476 | title | Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors | |
| P478 | volume | 19 | |